Prospective Evaluation of Intrathecal Targeted Drug Delivery for Cancer Associated Pain

This Registry study will prospectively evaluate the differences in treatment outcomes in terms of pain intensity, pain interference, concomitant medication use, health-related quality of life, opioid adverse effects, and healthcare utilization between targeted drug delivery and conservative medication management only groups.

Inclusion Criteria:Age of 21 and olderUncontrolled cancer-associated pain (pain score of >5 on NRS) despite oral use of 60 mg/d morphine equivalent a week prior to screeningAdverse side effects from long term opioid use defined as limiting or severely affecting patient's day to day functionLife expectancy of > 3 monthsExclusion Criteria:Active infectionsControlled pain without adverse side effects that are limiting day to day functionMechanical barriersObstruction of Cerebrospinal Fluid (CSF)